FDA approves ribociclib with aromatase inhibitor for HR advanced breast cancer

The U.S. Food and Drug Administration has approved ribociclib (KISQALI, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mIb2N6
via IFTTT